# Dr. Reddy's

Biosimilars at scale — affordable biosimilar mAbs.


Source: https://cn.bioecon.ru/companies/dr-reddys/
Updated: 2026-07-29

- 国家: India

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 2025财年营收US$38亿 | https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf |
| 员工人数 | 截至2025年3月31日全球员工26,944人 | https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf |
| 产能 | 每年为生物类似药生产1200万支西林瓶和1800万支预填充注射器 | https://www.drreddysbiologics.com/biologics, https://www.drreddysbiologics.com/contract-manufacturing |
| 生产基地 | 印度海得拉巴，包括位于 Genome Valley 的前沿生物制剂 CDMO 设施 | https://risecorp.co.in/where-are-dr-reddy-s-drugs-manufactured-inside-india-s-pharma-powerhouse, https://www.drreddysbiologics.com/biologics, https://www.drreddysbiologics.com/contract-manufacturing |
| 认证 | 19家生产设施通过ISO 45001认证；各设施符合全球质量标准，获得欧洲、拉丁美洲及其他国际市场监管机构的认证 | https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf, https://www.drreddysbiologics.com/biologics, https://www.drreddysbiologics.com/contract-manufacturing |
| 监管批准 | 利妥昔单抗生物类似药已获欧洲（EMA）及英国（MHRA）上市许可；地舒单抗生物类似药的BLA已获美国FDA受理 | https://www.drreddys.com/cms/cms/sites/default/files/2025-05/DRL_Q4FY25%20Earnings%20Call%20Transcript_9May2025.pdf, https://www.drreddys.com/cms/cms/sites/default/files/2025-05/Earnings%20Release_Q4FY25_090525_Final1.pdf, https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf, https://www.drreddysbiologics.com/biosimilars, https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm |
| 融资 | 该公司将年营收约8–10%投入研发,重点建设生物类似药管线;2026年联邦预算(Union Budget 2026)启动规模为₹10,000 crore的国家计划(Biopharma SHAKTI),以加强印度生物制品制造生态 [中等置信度] | https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biosimilars-innovation-are-dr-reddys-growth-pill-generics-to-remain-core-business-says-co-chairman-md-gv-prasad/articleshow/128687416.cms, https://www.drreddys.com/cms/cms/sites/default/files/2025-05/DRL_Q4FY25%20Earnings%20Call%20Transcript_9May2025.pdf, https://www.drreddys.com/cms/cms/sites/default/files/2025-06/Integrated%20Annual%20Report%202024-25.pdf |

独立来源: economictimes.indiatimes.com, risecorp.co.in, sec.gov

## 技术

- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)